( 1 of 2 ) |
United States Patent | 7,323,179 |
Balaban | January 29, 2008 |
The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includes Staphylococcus species.
Inventors: | Balaban; Naomi (Davis, CA) |
Appl. No.: | 10/358,448 |
Filed: | February 3, 2003 |
Application Number | Filing Date | Patent Number | Issue Date | ||
09839695 | Apr., 2001 | ||||
09054331 | Apr., 1998 | 6291431 | |||
60068094 | Dec., 1997 | ||||
Current U.S. Class: | 424/234.1 ; 424/184.1; 424/190.1; 424/236.1; 424/237.1; 424/239.1; 424/241.1; 424/246.1; 424/247.1; 424/257.1; 514/2.4; 514/2.7 |
Current International Class: | A61K 39/00 (20060101); A61K 39/02 (20060101); A61K 39/07 (20060101); A61K 39/08 (20060101); A61K 39/085 (20060101); A61K 39/108 (20060101); A61K 39/38 (20060101) |
Field of Search: | 424/184.1,185.1,243.1,244.1,134.1,190.1,234.1,236.1,237.1,241.1,239.1,246.1,247.1,257.1 514/16,12,2,8 530/300,329 |
6291431 | September 2001 | Balaban et al. |
6447786 | September 2002 | Novick et al. |
6689878 | February 2004 | Balaban et al. |
6747129 | June 2004 | Balaban et al. |
7067135 | June 2006 | Balaban |
7270969 | September 2007 | Watt et al. |
2002/0102271 | August 2002 | Balaban et al. |
2004/0072748 | April 2004 | Balaban |
2004/0077534 | April 2004 | Balaban |
2006/0252691 | November 2006 | Balaban |
2007/0009566 | January 2007 | Balaban |
2007/0009567 | January 2007 | Balaban |
2007/0009569 | January 2007 | Balaban |
2007/0015685 | January 2007 | Balaban |
2007/0025685 | February 2007 | Matsumoto |
2007/0071768 | March 2007 | Balaban |
2007/0092572 | April 2007 | Balaban et al. |
2007/0092575 | April 2007 | Balaban et al. |
0 395 099 | Oct., 1990 | EP | |||
1188831 | Mar., 2002 | EP | |||
WO 96 10579 | Apr., 1996 | WO | |||
WO 96/10579 | Apr., 1996 | WO | |||
WO 97 44349 | Nov., 1997 | WO | |||
WO 99 32133 | Jul., 1999 | WO | |||
WO 2005/009396 | Feb., 2005 | WO | |||
WO 2006/107945 | Oct., 2006 | WO | |||
WO 2006/122127 | Nov., 2006 | WO | |||
Balaban et al, Science, Apr. 17, 1998, 280:438-440. cited by examiner . Coasterton et al, Science, May 21, 1999, 284:1318-1322. cited by examiner . Ji et al, Science, Jun. 27, 1997, 276:2027-2030. cited by examiner . Balaban et al, JBC, Jan. 26, 2001, 276/4:2658-2667. cited by examiner . Balaban et al, J. Infectious Diseases, Feb. 15, 2003, 187:625-630. cited by examiner . Strauss, Science, Apr. 17, 1998, 280/5362:379 (3 pages). cited by examiner . Balaban, Trends in Microbiology, Dec. 1998, 6/12:463. cited by examiner . Otto, FEMS Microbiology Letters, 2004, 241:135-141. cited by examiner . Giacometti et al Peptides, 2004 "RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of Staphylococcal sepsis" Article in Press. cited by examiner . Smith et al, Chemistry and Biology, Jan. 2003, 10:81-89. cited by examiner . Domenico et al, Peptides, 2004, 25:2047-2053. cited by examiner . Giacometti et al, Antimicrobial Agents and Chemotherapy, Jun. 2003, 47/6:1979-1983. cited by examiner . Balaban et al, Antimicrobial Agents and Chemotherapy, Jul. 2004, 48/7:2544-2550. cited by examiner . Cirioni et al, Circulation, 2003, 108:767-771. cited by examiner . Balaban et al, Kidney International, 2003, 63:340-345. cited by examiner . Gov et al, Peptides, 2001, 22:1609-1620. cited by examiner . Balaban et al, Peptides, 2000, 21:1301-1311. cited by examiner . Ribeiro et al, Peptides, 2003, 24:1829-1836. cited by examiner . Lee, Trends in microbiology, Dec. 1998, 6/12:461-463. cited by examiner . Yang et al, Peptides, 24:1823-1828. cited by examiner . Vieira-da-Motta et al, Peptides 2001, 22:1621-1627. cited by examiner . Vieira-da-Motta et al, Abstracts of Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001, 41:46 Abstract only. cited by examiner . Korem et al, FEMS Microbiology Letters, 2003, 223:167-175. cited by examiner . Hartman et al, The Lancet, Mar. 21, 1998, 351:848-849. cited by examiner . Gov et al, JBC, Apr. 9, 2004, 279/15:14665-14672. cited by examiner . Dell'Acqua et al, J. Infectious Diseases, 2004, 190:318-320. cited by examiner . Ghiselli et al, Eur. J. Vasc. endovasc. Surg., 2004, 27:603-607. cited by examiner . Balaban et al, Science, Jan. 21, 2000, 287:391a (8 pages). cited by examiner . Balaban et al, PNAS, USA, Feb. 1995, 92:1619-1623. cited by examiner . Korem et al, Infection and Immunity, Oct. 2005, 73/10:6220-6228. cited by examiner . Yang et al, JBC, 2005, 280/29:27431-27435. cited by examiner . Yang et al, Vaccine, 2006, 24:1117-1123. cited by examiner . Balaban et al, JDG, 2003, 187:625-630. cited by examiner . Balaban et al, Clin. Orth., 2005, 437:48-54. cited by examiner . Korems et al, Infection and Immunity, 2005, 73/10:6220-6228. cited by examiner . Solomon et al, J. Bacteriology, 2003, 185/21:6425-6433. cited by examiner . Chakraborty et al, J. Bacteriology, 1992, 174/2:568-574. cited by examiner . Frasier et al, Appl. Environ. Microbiol., 2000, 66:4696-4704. cited by examiner . Sleator et al, J. Clin. Invest., 2004, 113:274-284. cited by examiner. |